🇺🇸

US SEC Filing Intelligence

· daily

US Executive Officer Management Changes SEC — August 28, 2026

The 29 filings reveal a day of significant executive and director changes across diverse sectors, with a notable concentration of CFO transitions and departures. Key themes include a wave of CFO changes at Pinterest, Lindsay Corp, and Vyome Holdings, alongside several director resignations and board appointments. While most changes are routine, Getty Images stands out with a highly material $92.3 million adverse judgment and a director resignation, creating a clear risk flag. Insider activity is limited, but retention bonuses at Latch and Pro-Dex suggest efforts to stabilize leadership. Period-over-period comparisons are sparse in these filings, but the capital allocation data from Steele Bancorp shows a significant increase in executive retirement benefits, signaling a focus on long-term retention. The overall sentiment is neutral, with isolated positive signals from board appointments at IonQ and Altria, and negative signals from Getty Images and the CFO departures at Pinterest and Outset Medical.

29 high priority 29 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — August 28, 2026

The USA Bankruptcy & Insolvency stream for August 28, 2026, reveals a concentrated wave of biopharma Chapter 11 filings, with both BioXcel Therapeutics and Sangamo Therapeutics entering court-supervised restructuring to monetize core assets via stalking horse auctions. BioXcel's deal with Teva Pharmaceuticals for $57.5M upfront plus up to $87.5M in milestones provides a floor valuation, while Sangamo's sale of its Fabry gene therapy asset (ST-920) to PTC Therapeutics lacks disclosed upfront consideration, signaling potentially distressed pricing. Both filings underscore a sector theme of cash-constrained biotechs liquidating pipeline assets to repay creditors, with no revenue growth or insider buying to offset negative sentiment. The absence of period-over-period comparisons or forward guidance in these initial filings limits trend analysis, but the materiality scores (10/10 and 9/10) highlight high-impact events for investors monitoring bankruptcy recoveries and distressed asset valuations.

2 high priority 2 total filings
· daily

USA Insider Trading Pulse — August 28, 2026

The August 28, 2026, insider trading pulse reveals a market with a distinct bifurcation: aggressive insider buying in select value-oriented and small-cap names (American Assets Trust, Matador Resources, 17 Education) contrasts sharply with significant, often 10b5-1 plan-driven, selling by senior executives at large-cap technology and industrial firms (IBM, Alcoa, Intuit). A dominant theme is the high volume of routine, non-actionable filings—director stock awards, tax-withholding transactions, and unparseable EDGAR documents—which constitute the majority of the 50 filings. However, the actionable signals are concentrated in a few high-conviction insider purchases, notably the Executive Chairman of American Assets Trust deploying $2.26M, and a notable cluster of selling activity at Lightbridge Corp and Caesars Entertainment. The data suggests a cautious posture among insiders at larger, more liquid names, while signaling potential deep value or turnaround conviction in smaller, out-of-favor sectors. No significant period-over-period financial trends or forward-looking guidance changes were present in the filings, making the insider transaction patterns the primary source of intelligence.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 28, 2026

The US M&A landscape is bifurcated: two new SPAC IPOs (NorthStrive, Rainier) signal continued appetite for blank-check vehicles, but three existing SPACs (Andretti, Constellation, Allegro) are struggling to close deals, with Allegro's merger termination and Constellation's seventh extension highlighting execution risk. A major strategic acquisition closed in the critical minerals space (Energy Fuels buying ASM for $243M), while Intrusion Inc. secured emergency debt financing at a 7.7% discount, suggesting financial distress. Period-over-period data reveals a clear pattern of SPACs burning cash with no revenue, while Energy Fuels stands out as the only filing with a completed, value-creating transaction. Insider activity is absent across all filings, but forward-looking data points to a catalyst-rich September with Andretti's shareholder vote and Constellation's next deadline. The sector theme is a tale of two markets: capital is flowing into new SPACs, but existing ones face a credibility crisis with investors demanding deals or liquidation.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 28, 2026

Overnight filings reveal a bifurcated market landscape with significant distress signals in the healthcare and technology sectors, offset by strategic capital deployment in infrastructure and energy. The most critical development is BioXcel Therapeutics' Chapter 11 filing with a stalking horse bid from Teva Pharmaceuticals, highlighting the high-risk nature of biotech. Lumentum Holdings saw a coordinated wave of insider selling by multiple top executives, including the CEO and CFO, totaling over $6.7 million, a bearish signal for the optical components sector. Conversely, a major strategic investment in VNET Group by a consortium backed by CATL signals a bullish long-term bet on Chinese data center infrastructure. Hafnia Ltd reported a 24.8% decline in net income, reflecting a challenging tanker market, while Netcapital faces a Nasdaq delisting risk due to filing delays. The overall theme is one of caution, with capital being redeployed from distressed assets into strategic long-term plays, and insider activity suggesting management concern in specific names.

36 high priority 14 medium 50 total filings
· daily

New Drug Approvals (Original) — August 27, 2026

The August 27, 2026 FDA approval stream delivered three biosimilar approvals (SOCORRO N1's NITROGLYCERIN, ZYDUS LIFESCIENCES' RIFABUTIN, and LAURUS' TICAGRELOR), with zero NMEs, zero label expansions, and zero bullish signals. The period is characterized by low commercial materiality, as all three approvals are for established generic/biosimilar molecules with NOT_DISCLOSED peak sales estimates and no disclosed exclusivity or pricing power. No dominant therapeutic area theme emerges, as the approvals span cardiovascular (NITROGLYCERIN, TICAGRELOR) and anti-infective (RIFABUTIN) categories. The highest-conviction signal is the neutral entry of LAURUS into the TICAGRELOR market, which could pressure originator AstraZeneca's BRILINTA franchise over time, though the lack of disclosed market position limits conviction. Key risk is the absence of NME or breakthrough approvals, signaling a dry period for high-value catalysts and potential pipeline weakness across the sector.

3 total filings
· daily

VA Healthcare & Services Contracts — August 27, 2026

This digest covers a single $136.95M civilian contract awarded by the Department of Veterans Affairs to UnitedHealth Group's OptumRx subsidiary for pharmacy benefit management services. The contract is a firm-fixed-price delivery order with a short four-month performance period, generating a high monthly run rate of ~$34M. While the award validates OptumRx's competitive position in the stable VA market, the short duration and competitive bidding environment introduce uncertainty regarding revenue recurrence. The neutral signal strength reflects balanced risk-reward, with no bullish or bearish catalysts identified in this isolated award.

1 total filings
· daily

New Federal Contractors — August 27, 2026

This digest of five new federal contracts, totaling $662.4M in obligations, reveals a predominantly civilian-focused procurement environment, with only one defense-related award (HII Mission Technologies Corp at $157.3M). The highest-conviction signal is the bullish, cost-plus award fee contract for Noridian Healthcare Solutions, LLC ($116.8M initial obligation, up to $573.6M total) from CMS for Medicare Fee-For-Service support, offering stable, low-risk revenue. A key risk is the short-duration, firm-fixed-price PBM contract for OptumRx ($136.9M over four months), which shifts cost risk to the contractor and lacks long-term visibility. The digest highlights a trend toward large, recurring civilian agency contracts in healthcare and social services, with defense exposure limited to a single Navy engineering support award.

5 total filings
· daily

Significant Contract Modifications ($10M+) — August 27, 2026

This digest covers five government contract actions totaling $662.4 million in obligations, with only one defense-related award (HII Mission Technologies at $157.3M) and four civilian contracts. The dominant theme is civilian agency healthcare and IT services, led by Noridian Healthcare Solutions' $116.8M CMS contract (potential $573.6M over 10 years) and OptumRx's $136.95M VA pharmacy benefit management order. The highest-conviction signal is HII's Navy engineering support contract, which provides a five-year recurring revenue stream and validates Huntington Ingalls' diversification into services. A key risk is the expired Business Integra NASA IT contract ($149.3M obligated), which creates a revenue gap for that contractor and signals potential re-compete vulnerability.

5 total filings
· daily

Contract Deobligations Alert — August 27, 2026

This digest covers $662.4M in federal contract obligations across five awards, with only one defense-related contract (HII Mission Technologies at $157.3M) and four civilian awards totaling $505.1M. The dominant theme is stable, recurring civilian agency spending—particularly healthcare (VA OptumRx, CMS Noridian) and workforce training (DOL Management & Training)—rather than defense growth. The highest-conviction signal is the Noridian Healthcare Solutions CMS contract ($116.8M obligated, $573.6M potential), which offers low-risk cost-plus award fee revenue through 2032. Key risks include the short duration of the OptumRx VA PBM contract (4 months) and the expired status of the Business Integra NASA IT contract, which limits forward visibility. Investors should watch for option exercises on the Noridian and HII contracts as catalysts for sustained revenue.

5 total filings
· daily

Contract Option Exercises — August 27, 2026

This digest covers $662.4M in contract option exercises from August 27, 2026, with only 1 of 5 contracts defense-related (HII Mission Technologies' $157.3M Navy engineering award), signaling a civilian-heavy procurement week. The dominant theme is healthcare and social services administration, with OptumRx ($136.95M VA PBM) and Noridian Healthcare Solutions ($116.8M CMS Medicare contract) representing $253.7M combined. The highest-conviction signal is Noridian's $573.6M potential value cost-plus award fee contract, offering low-risk, stable margins tied to mandatory Medicare funding. Key risk: the aggregate includes a negative outlayed amount (-$100,687) on HII's contract, suggesting potential accounting or funding issues that warrant monitoring for broader Navy procurement trends.

5 total filings
· daily

Federal Professional Services Contracts — August 27, 2026

This digest covers a single, high-value contract award totaling $157.3 million to HII Mission Technologies Corp, a subsidiary of Huntington Ingalls Industries (HII), for engineering services supporting the Department of the Navy. The contract is 100% defense-related, reflecting stable demand for naval sustainment in strategic locations like Pearl Harbor. The highest-conviction signal is bullish, driven by a five-year recurring revenue stream with options that could bring the total value to $240.1 million. However, a key risk is the negative outlayed amount (-$100,687), which may indicate early-stage funding adjustments or accounting anomalies that require monitoring.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — August 27, 2026

This digest covers a single, large civilian IT contract awarded to Business Integra Technology Solutions, Inc. by NASA, with a total obligation of $149.3 million. The contract, valued at $206 million including options, is now expired (ended July 2022), creating a significant revenue gap for the contractor. The cost-plus-fixed-fee structure historically provided stable margins, but the lack of current revenue visibility and the 8(a) set-aside nature of the award introduce execution and competitive risks for the company. The highest-conviction signal is the neutral-to-bearish implication of the contract's expiration, which creates a material overhang for Business Integra's future earnings. A key risk is the absence of any follow-on contract or re-compete data, suggesting potential revenue decline for the contractor.

1 total filings
· daily

All HHS Contracts — August 27, 2026

The single contract analyzed, valued at $116.8 million in initial obligation, is entirely civilian, awarded by the Centers for Medicare and Medicaid Services (CMS) to Noridian Healthcare Solutions, LLC. The total potential value of $573.6 million over up to 10 years provides significant long-term revenue visibility, with the cost-plus award fee structure reducing profit risk for the contractor. The highest-conviction signal is the stable, mandatory nature of the Medicare Fee-For-Service program, which insulates funding from discretionary budget cuts. A key risk is the reliance on option exercise and performance metrics to realize the full contract value, as well as the lack of a competitive moat given the full-and-open competition.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — August 27, 2026

This digest covers $662.4M in aggregate obligations across five contracts, with only one (20%) defense-related, reflecting a heavy civilian tilt. The highest-conviction signal is Noridian Healthcare Solutions' $116.8M cost-plus award fee contract with CMS, offering low-risk, stable Medicare revenue with a $573.6M ceiling. HII Mission Technologies' $157.3M Navy engineering support contract is the largest defense award, providing five-year revenue visibility but with an anomalous negative outlayed amount that warrants monitoring. The dominant sector theme is civilian healthcare administration, with two contracts totaling $253.7M from HHS and VA. A key risk is the short duration of OptumRx's $137M VA PBM contract (four months), which creates revenue discontinuity and exposes UnitedHealth Group to re-compete pressure.

5 total filings
· daily

High-Value Federal Grants ($5M+) — August 27, 2026

This digest covers $662.4M in high-value federal grants and contracts, with only 1 of 5 awards defense-related (HII Mission Technologies' $157.3M Navy engineering support), underscoring a heavy civilian tilt. The dominant theme is healthcare and social services administration, driven by Noridian Healthcare Solutions' $116.8M CMS Medicare contract and OptumRx's $136.9M VA pharmacy benefit management award. The highest-conviction signal is Noridian's cost-plus award fee structure, which provides low execution risk and stable margins over a potential 10-year term. A key risk is the short, four-month performance period for OptumRx's VA contract, which creates revenue discontinuity and exposes UnitedHealth Group to recompete uncertainty.

5 total filings
· daily

General Federal Contracts — August 27, 2026

This digest covers $662.4 million in total obligations across five contracts, with only one of five being defense-related (HII Mission Technologies' $157.3M Navy engineering support), underscoring a civilian-heavy stream. The dominant theme is stable, recurring civilian agency spending, led by Noridian Healthcare Solutions' $116.8M CMS Medicare contract (up to $573.6M total) and OptumRx's $137M VA pharmacy benefit order. The highest-conviction signal is Noridian's cost-plus award fee structure, which provides low-risk, predictable margins on a mandatory entitlement program. Key risks include the short duration of OptumRx's four-month PBM contract and the expired status of Business Integra's NASA IT support award, limiting forward revenue visibility. The aggregate average signal strength of 5.8/10 reflects a mix of steady civilian revenue streams with no high-growth or disruptive defense catalysts.

5 total filings
· daily

All NASA Contracts — August 27, 2026

This digest analyzes a single NASA contract awarded to Business Integra Technology Solutions, Inc., valued at $149.3 million obligated out of a $206 million ceiling. The contract is entirely civilian (NASA), with zero defense-related spending, and represents a mature, expired cost-plus-fixed-fee IT support award at Goddard Space Flight Center. The highest-conviction signal is neutral, reflecting the contract's low risk profile but lack of future revenue visibility due to its 2022 end date. A key watch item is the potential for a re-compete or follow-on opportunity at NASA Goddard, which could signal continued IT infrastructure investment.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — August 27, 2026

The 16 filings from S&P 500 Technology constituents reveal a sector bifurcated between strong top-line growth and cautious insider sentiment. Revenue growth is robust, led by Marvell Technology (+37% YoY) and CrowdStrike (+25.8% YoY), while Salesforce (+10.8% YoY) and Autodesk (+16% YoY) show solid subscription-driven expansion. However, profitability trends are mixed: Salesforce's net income surged 86.9% YoY on investment gains, but its operating income was flat, and Marvell's non-GAAP gross margin is guiding lower sequentially. A striking pattern is the wave of insider selling: 8 separate Form 4 filings show executives and directors selling stock, including the CEO of Arista Networks ($1.94M), CFO of Applied Materials ($3.59M), and CFO of AMD ($1.82M), all under 10b5-1 plans, signaling that management is taking profits at current elevated valuations. Capital allocation is aggressive, with Salesforce repurchasing $27.4B in stock (halving equity) and CrowdStrike spending $881M on acquisitions. Forward-looking data is bullish: Marvell raised its FY2027 and FY2028 revenue outlook, and Autodesk raised its full-year billings guidance, but margin dilution from M&A is a recurring concern. The sector themes point to AI-driven demand as the primary growth engine, with data center revenues surging, but rising debt costs and margin compression from acquisition integration are key risks.

13 high priority 3 medium 16 total filings